TP53 Mutations Identify High-Risk Events for Peripheral T-Cell Lymphoma Treated With CHOP-Based Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
Blood Adv 2023 Apr 20;[EPub Ahead of Print], WT Johnson, N Ganesan, ZD Epstein-Peterson, AJ Moskowitz, RN Stuver, CR Maccaro, N Galasso, T Chang, N Khan, U Aypar, NE Lewis, AD Zelenetz, ML Palomba, MJ Matasar, A Noy, AM Hamilton, PA Hamlin, PC Caron, DJ Straus, AM Intlekofer, CL Batlevi, A Kumar, CN Owens, CS Sauter, L Falchi, JK Lue, SA Vardhana, GA Salles, A Dogan, ND Schultz, ME Arcila, SM HorwitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.